
Please try another search
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Carmine N. Stengone | 49 | 2018 | President, CEO & Director |
Evert B. Schimmelpennink | 53 | 2022 | Independent Chairman of the Board |
Lori M. Lyons-Williams | 48 | 2020 | Independent Director |
Todd R. Brady | 46 | 2019 | Independent Director |
Troy A. Ignelzi | 57 | 2024 | Independent Director |
Sarah Boyce | 53 | 2024 | Independent Director |
Olivia C. Ware | 68 | 2024 | Independent Director |
Gines Diego Miralles | 62 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review